R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 30.05 PLN 1.18% Market Closed
Market Cap: 694.8m PLN
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+150%
Revenue
Forecast
+25%
Operating Income
Forecast
+50%
Net Income
Forecast
+44%

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 75.12 PLN with a low forecast of 48.48 PLN and a high forecast of 104.27 PLN.

RVU Lowest Forecast
Wall Street Target
48.48 PLN
61% Upside
RVU Average Forecast
Wall Street Target
75.12 PLN
150% Upside
RVU Highest Forecast
Wall Street Target
104.27 PLN
247% Upside
Lowest
Price Target
48.48 PLN
61% Upside
Average
Price Target
75.12 PLN
150% Upside
Highest
Price Target
104.27 PLN
247% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
VIMTALABS
Vimta Labs Ltd
38% Downside
TKNO
Alpha Teknova Inc
104% Upside
I
INNOVACAP
Innova Captab Ltd
30% Upside
R
301333
R&G PharmaStudies Co Ltd
47% Upside
VIMTALABS
Vimta Labs Ltd
38% Downside
TKNO
Alpha Teknova Inc
104% Upside
I
INNOVACAP
Innova Captab Ltd
30% Upside
R
301333
R&G PharmaStudies Co Ltd
47% Upside
SFZN
Siegfried Holding AG
25% Upside
CHEMM
Chemometec A/S
17% Upside
LAB
Standard BioTools Inc
122% Upside
SKAN
SKAN Group AG
31% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 11 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 18%. The projected CAGR for the next 3 years is 25%.

18%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-33%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss
What are analyst estimates?

See Also

Summary
RVU intrinsic value, competitors valuation, and company profile.
DCF Valuation
RVU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RVU stock valuation using valuation multiples.
Wall Street Estimates
RVU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RVU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
75.12 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 75.12 PLN with a low forecast of 48.48 PLN and a high forecast of 104.27 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
25%

For the last 11 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 18%. The projected CAGR for the next 3 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.